The aim of this study was to detect routinely determinable prognostic parameters that allow a better stratification of patients and improved therapy allocation in a selected patient cohort with metastatic NSCLC and high PD‐L1 expression without targetable genetic alterations in the first‐line situation. This evidence concerns the gene CD274 and non-small cell lung carcinoma.